Royalty Report: Drugs, Cannabis, Drug Discovery – Collection: 309817


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Cannabis
  • Drug Discovery
  • Pain
  • Gastrointestinal

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 309817

License Grant
Pursuant to an acquisition, the Canadian Licensee secured certain intellectual property rights to PEA from Italian Licensor.

The License Agreement grants an exclusive, worldwide license, excluding Italy and Spain where the Licensee is not licensed and Licensor remains entitled to commercialize the Licensed Products, to research, manufacture and commercialize products.

The License also gives Licensee the right to use the Licensed IP in the development of a prescription drug for the treatment of the cytokine storm associated with COVID-19.  In addition, under the terms of the License, if Licensor develops or commercializes a prescription drug for the treatment of any other human condition unrelated to pain and chronic pain (a Different Prescription Drug) in its territory, the Licensee has a first refusal right to use Licensors patents to develop and commercialize this Different Prescription Drug in its territory (i.e. worldwide excluding Italy and Spain). Should the Licensee exercise this right, but then fail to demonstrate commercially reasonable efforts to develop the Different Prescription Drug in the two years following,  Licensor would be free to exploit and/or license to third parties the use of the patents for the Different Prescription Drug.  The Licensees -201 COVID-19 Trials are subject to such requirements.  

Finally, the License provides the Licensee with a non-exclusive license to use Licensors scientific and technical know-how with respect to ultramicronized-PEA in connection with the development or commercialization of the Licensed Products.

License Property
The Licensed Products are those that are developed using certain proprietary formulations of PEA or  ultramicronized-palmitoylethanolamide owned by Licensor and that are to be used to treat chronic kidney disease in humans or, if a prescription drug, any other human condition that is related to pain and chronic pain.

The proprietary formulations will relate to patents and other intellectual property rights to ultramicronized-PEA owned by Licensor.  PEA is a naturally occurring substance that is produced within the body in response to inflammation and interacts with endocannabinoid receptors throughout the body, including the central nervous system.

The synthetic drug, known as ultramicronized palmitoylethanolamide (micro PEA), mimics a molecule found in cannabis and is believed to have anti-inflammatory properties.

Field of Use
The Licensee received approval from the FDA to apply to run a clinical trial of a cannabis-derived drug on coronavirus patients.  The drug mimics molecules naturally found in marijuana that bind to receptors and play a role in mitigating pain and fighting inflammation

The Licensee plans to advance the research & development of ultramicronized-palmitoylethanolamide (ultramicronized-PEA or -201) to commercialization through studies and clinical trials, including anticipated timing and associated costs; the status of the Corporations IND application with the FDA to conduct the -201 COVID-19 Trials for the use of -201 to treat COVID-19, including the timing, completion and outcomes of any trials or whether -201 may be effective and feasible in treating COVID-19.

The Licensee is a clinical-stage biotechnology company that is focused on bioscience, including research and development  and clinical development of synthetic cannabinoid based treatments of certain disease conditions with an aim to improve patient outcomes.

FSD-201 mimics endocannabinoids, neurotransmitters found in marijuana that bind to CB2 receptors.
These receptors play a large role in the body’s immune system, particularly in mitigating pain and fighting inflammation.
The hope its that FSD-201 could help mitigate a dangerous overreaction to the virus by the body’s immune system called a cytokine storm.
These so-called storms occur when the body doesn’t just fight off the virus but also attacks its own cells and tissues.
In cases of COVID-19, the disease caused by the virus, cytokine storms can trigger respiratory distress.
This can lead to multi-system organ failure and cause the lungs’ airs sacs to fill up with fluid, the result being pneumonia.
‘Severe COVID-19 is characterized by an over-exuberant inflammatory response that may lead to a cytokine storm.

IPSCIO Record ID: 359060

License Grant
The Parties entered into a sponsored research agreement to conduct research and development efforts relating to Licensors COVID-19 and rheumatoid arthritis (RA) product candidates. The focused is on characterizing the activity of cannabinoids in RA and in hyperinflammatory syndrome related to COVID-19.

In accordance with the terms of the Research Agreement, Israelis Licensee and Israelis Licensor will have joint ownership of any IP created as a result of research programs covered by such agreement. In connection with the Research Agreement, Licensor agreed not to work, study or develop any technologies with other entities that compete with our work with Licensor for our COVID-19 product candidate or RA product candidate for a term of three and seven years, respectively, from the end of the parties’ collaboration with respect to the COVID-19 product candidate and seven years from the end of the term of the Research Agreement with respect to the RA product candidate.

License Property
Cannabidiol, or CBD, oil is derived from CBD strains with low levels of Tetrahydrocannabinol, or THC. The discovery platform currently focuses the use of CBD oil, one of the cannabinoids in cannabis plants, as the active pharmaceutical ingredient, or API, for our RA product candidate and COVID-19 product candidate.

The Licensor  have been conducting research on the use of cannabis to treat disorders with widespread inflammatory responses, such as RA and COVID-19. Parties hope that by decoding the cannabinoid mechanism of action during inflammatory storms, the Parties can treat inflammation associated with COVID-19 where conventional drugs and other therapies have failed.

Field of Use
Field of use is for the treatment in RA and in hyperinflammatory syndrome related to COVID-19.

Rheumatoid arthritis (RA) is a long-term autoimmune disorder. COVID-19 is a virus infection.

IPSCIO Record ID: 340061

License Grant
Italian Licensor grants the Licensee an exclusive, worldwide license (excluding Italy, and subject to a first refusal right maintained by Licensor, any other country in Europe) to research, manufacture and commercialize products using certain proprietary formulations of ultra-micro PEA (the Licensed Products) to treat gastro-intestinal diseases in canines and felines. The License Agreement provides that the Licensee shall develop the Licensed Products with a view to submitting an Investigational Animal Drug Application with the FDA within thirty-six (36) months of the date of the agreement and shall submit a New Animal Drug Application within sixty (60) months of the effective date of the agreement.
License Property
Licensed Product is ultra- micro PEA (ultramicronized-palmitoylethanolamide or ultramicronized PEA),  a veterinary anti-inflammatory prescription drug with anti-inflammatory properties.
Field of Use
Field of use is to treat gastro-intestinal diseases in canines and felines.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.